Commentary: Opponents need to stop equating abortion with eugenics
By Carla Hall,
Los Angeles Times
| 05. 01. 2023
Among the dubious points that U.S. District Judge Matthew Kacsmaryk makes in his recent ruling suspending the Food and Drug Administration’s authorization of mifepristone is that abortion is part of the now-reviled practice of eugenics.
That clinical-sounding word refers to the appalling and scientifically incorrect theory that was promoted in the past by government and prominent civic leaders — and even the U.S. Supreme Court — to justify the forced sterilization of women and men deemed feeble-minded, mentally ill, criminal or poor to prevent them from bearing offspring who might sully the gene pool.
In his decision, now blocked by the Supreme Court, Kacsmaryk quoted a 2019 opinion by Supreme Court Justice Clarence Thomas noting that “abortion has proved to be a disturbingly effective tool for implementing the discriminatory preferences that undergird eugenics.”
Kacsmaryk’s reference to eugenics came out of the blue near the end of his opinion, apparently in response to a declaration from economist Jason Lindo — submitted as part of the government’s court filings — that taking easily accessed medication abortion pills off the market would make...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...